A Randomized, Sponsor-Open, Investigator-Blind, Subject-Blind, Placebo-Controlled, Single Ascending Dose, to Investigate the Safety, Tolerability and Pharmacokinetics of RO7062931 Following Subcutaneously Administration in Healthy Chinese Volunteers
Phase of Trial: Phase I
Latest Information Update: 23 Jul 2018
At a glance
- Drugs RO 7062931 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Roche
- 16 Jul 2018 Planned End Date changed from 6 Nov 2018 to 12 Mar 2019.
- 16 Jul 2018 Planned primary completion date changed from 6 Nov 2018 to 12 Mar 2019.
- 23 May 2018 Status changed from not yet recruiting to recruiting.